12-21-2018: Vericel Corporation (VCEL): Leg Cartilage and Burn Repair

(WAIT FOR PAGE TO LOAD COMPLETELY BEFORE LINKS WORK.)

Corporate Webpages
Company Profile
Company History
News
Comparison with Peers
Bond Issue
Zenith Index
Financial Statements
Avg. P/E to Current P/E
Financial Ratios
Intrinsic Value (Disc. CashFlow)
Fair Value Estimator
Projected Earnings
Research Reports
Analysts' Opinions
Insider Activity
Institutional Activity
Sentiment
Short Interest
Standard & Poor's
Management's Discussion
Channel Potential
MACD Histogram
Intraday Chart
Val Idea
Stock Consultant
Point & Figure Chart
Wall Street Analyzer
Marketspace Chart
Time Series Forecast
Neural Network Prediction
Stock Options
Ultimate Trading Systems
Recommendation

Vericel Corporation

Vericel Corporation (VCEL) was picked by us for analysis because it appeared to have strong support from analysts, but it had from the start several immediate disappointments. It produces three main drug products, MACI for repair of knee cartilage damage, and Carticel, used to repair damage to the femoral condyle (leg cartilage). The third is "Epicel", a skin replacement for patients with deep burns. It also provides assistance to others in getting drugs approved through the FDA process.

We felt the corporation website was totally inadequate. Beside being somewhat vague about its products and services, it featured the "latest" annual report that was two years old and a CEO Letter to Shareholders that was four years old. The company has significant insider selling going on, and comparing to different data sources, the company may have even misrepresented stock option perquisites it was handing out to managers. For example, in our main data source for executive compensation, no stock option perquisites are listed at all, but in the company's "Management Discussion" excerpts on this site the awards were considerable, again showing a disdain for other shareholders. Some data looks very good in that executives appear modestly compensated, but the data we have is suspect.

In addition to that the corporation has been busy floating new shares of stock thus diluting the value of existing shares.

Aside from all that, the stock has an absolutely terrible Zenith Index indicating very poor fundamentals. Problems exist across the board from a net negative tangible asset value to straight losses for the past five years, cash flow problems, and so on. Nor do we see any great new pharmaceutical discoveries on the horizon for this company. But despite all this, institutions are net acquirers. They obviously see something, along with the analysts, that we don't.

We may not understand all the implications, not being certified public accountants, but we missed seeing an approval statement from a registered independent certified public accounting firm for management reports to SEC subsequent to 2016, at which time we believe it was PriceWaterhouseCoopers. The mere absence may or may not mean anything, but because we could not find it, we gave a negative rating to the "Management Discussion" section, partly because it was too short. Normally we rate highly brief, short, problem-free unqualified management reporting statements (less work for us to decifer), but there such a thing as "too short."

The stock is currently in one of the worst-performing industry groups, "Medical-Biomedical", and also one of the most competitive. However, it is one of the strongest performers in that group.

Amazingly, Standard & Poor's gives the stock a high rating. After years of losses, the company may be just starting to turn profitable, and these types of a turnaround situation often lead to explosive share price increases, so there is risk in shorting this stock. 



[Home]
Corporate Wepages

Trade Mark
01
2
3
4
5
6
7
8
9
10



[Home]
Company Profile

Profile



[Home]
Company History
6


[Home]
News

Click Here for News Archives



[Home]
Comparison

Comparison

Groups 1
Groups 2
Groups 3


Companies 1
Companies 2
Companies 2
Companies 2
Companies 2

Similar Companies Performance:

55 56
57 58
59 60


[Home]
Bond Issue

22 23



[Home]
Zenith Index

Under current market conditions, a Zenith Index Score of 1.20 or above is required for a positive rating on this factor. 1.21 -1.30 is considered acceptable, 1.30-1.40 is considered strong and
> 1.40 is considered exceptionally strong. Accounting statements in this section often contain mistakes, especially in earlier years' totals, but data is deemed sufficient for us to give a rating. More accurate financial statements follow in the next section.

Vericel Corporation (VCEL)                                Exchange: Nasdaq
64 Sidney Street
Cambridge, MA 02139              Sector: Healthcare
United States                    Industry: Biotechnology

Vericel Corporation, a commercial-stage biopharmaceutical company,
researches, develops, manufactures, markets, and sells patient-specific
expanded cellular therapies to repair and regenerate damaged tissues and
organs. It markets autologous cell therapy products, including MACI, an
autologous cellularized scaffold product for the repair of symptomatic,
and single or multiple full-thickness cartilage defects of the knee; and
Carticel, an autologous chondrocyte implant for the repair of
symptomatic cartilage defects of the femoral condyle caused by acute or
repetitive trauma in patients that have inadequate response to a prior
arthroscopic or other surgical repair procedure. The company also
markets Epicel, a permanent skin replacement humanitarian use device for
the treatment of patients with deep-dermal or full-thickness burns. In
addition, it develops ixmyelocel-T, a patient-specific multicellular
therapy that has completed Phase IIb clinical trial for the treatment of
advanced heart failure due to ischemic dilated cardiomyopathy. The
company was formerly known as Aastrom Biosciences, Inc. Vericel
Corporation was founded in 1989 and is headquartered in Cambridge,
Massachusetts.

Last Trade:  17.10                           52-Week Range:  18.87 -   4.60
Employees: 205                               Avg.Volume:   1,030,130 Shares

Corporate Governance:
Pillar scores are Audit: 2; Board: 7; Shareholder Rights: 5; Compensation: 6.
         (A lower number means less governance risk.)

EPS: -0.34    Dividend Amount: $ 0.00          Yield:  0.00%
             Ex-Dividend Date: N/A             Payout Ratio:   0.00

Key Statistics:

    Trailing P/E:   0.00                      Target Price:  21.10

Qrtly Stock Price Growth (yoy): 252.58%               Beta:   0.00
Qrtly S&P Index   Growth (yoy):  57.70%        Short Ratio:   4.11%
    Qrtly Revenue Growth (yoy):  -3.35%         Shares Out:  43350000
   Qrtly Earnings Growth (yoy):   0.00%

          Book Value:   2.19                    Debt/Equity:  18.29%
    Price/Book Value:   7.82        Operating Profit Margin:  10.51%
         Price/Sales:   8.94                  Profit Margin: -15.80%
         Market Cap:     741,239,000       Return on Equity: -23.54%
    Enterprise Value:     660,770,000      Return on Assets:  -6.61%

    Operating Cash Flow:     -2,190,000
         Free Cash Flow:     -3,060,000



Annual Income Statement:                          (All numbers in thousands)
  Period Ending                             12/31/2017  12/31/2016  12/31/2015

  Total Revenue                                 63,924      54,383      51,168
  Cost of Revenue                               30,354      28,307      26,470
  Gross Profit                                  33,570      26,076      24,698

Operating Expenses:
  Research & Development                        12,944      15,295      18,890
  Selling, General & Administrative             35,610      27,388      22,479
  Non-Recurring Expenses                             0           0           0
  Other Operating Expenses                           0           0           0
  Total Operating Expenses                      78,908      70,990      67,839

Operating Income or Loss                       -14,984     -16,607     -16,671

Income from Continuing Operations:
  Total Other Income/Expenses Net               -2,302      -2,959         331
  Earnings Before Interest & Taxes             -14,984     -16,607     -16,671
  Interest Expense                              -1,107        -314          -9
  Income Before Taxes                          -17,286     -19,566     -16,340
  Income Tax Expense                                 0           0           0
  Minority Interest                                  0           0           0

Net Income from Continuing Op.s                -17,286     -19,566     -16,340

Non-recurring Events:
  Discontinued Operations                            0           0           0
  Extraordinary Items                                0           0           0
  Effect of Accounting Changes                       0           0           0
  Other Items                                        0           0           0
  Net Income                                   -17,286     -19,566     -16,340
  Preferred Stock & Other Adjustments                0           0           0

Net Income Avail to Common Shares              -17,286     -27,145     -23,076



Annual Cash Flow Statement:                   (All numbers in thousands)
  Period Ending                         12/31/2017    12/31/2016    12/31/2015

  Net Income                               -17,286       -19,566       -16,340

Operating Activities:
  Depreciation                               1,612         1,886         1,592
  Adjustments to Net Income                  4,058         5,949         2,814
  Changes in Accounts Recv'bls              -1,177        -6,174        -2,728
  Changes in Liabilities                    -1,361        -1,076         1,726
  Changes in Investories                      -657        -2,245           -86
  Changes in other Oper'g Acts               1,628         1,334          -324

Total Cash Flow f Operations               -13,183       -19,892       -13,346

Investing Activities:
  Capital Exenditures                       -1,510        -1,415        -2,427
  Investments                                    0             0             0
  Other Cash Flows fr Investing                  0       -35,101             0

Total Cash Flows from Investing             -1,510        -1,415        -2,392

Financing Activities:
  Dividends Paid                                 0             0             0
  Sale of Purchase of Stock                      0             0             0
  Net Borrowings                             6,753        10,272           -35
  Other Cash Flows fr Financing               -406           -23             0

Total Cash Flows from Financing             18,577        29,704           -24

  Effect of Exchange Rate Chg                    0             0             0

Change in Cash & Cash Equiv.                 3,884         8,397       -15,762




Annual Balance Sheets:                              (All Numbers in Thousands)
  Period Ending                          12/31/2017    12/31/2016    12/31/2015
Current Assets:
  Cash & Cash Equivalents                    26,862        22,978        14,581
  Short Term Investments                          0             0             0
  Net Receivables                            18,270        17,093        10,919
  Inventory                                   3,793         3,488         1,379
  Other Current Assets                        1,581         1,164           464
  Total Current Assets                       50,506        44,723        27,343

  Long-Term Investments                           0             0             0
  Property, Plant & Equipt                    4,071         3,875         4,049
  Goodwill                                        0             0             0
  Intangible Assets                               0   -29,173,196             0
  Accumulated Amortization                        0             0             0
  Other Assets                                    0             0             0
  Deferred LT Asset Charges                       0             0             0

Total Assets                                 54,577        48,598        34,309

Current Liabilities:
  Accounts Payable                            5,552         6,535         7,588
  Current Portion LT Debt                       350           779             0
  Other Current Liabilities                   1,615         1,016           917
  Total Current Liabilities                  13,090        12,853         12,108

  Long Term Debt                             16,888         9,350            71
  Other Liabilities                           2,059         1,687             0
  Deferred LT Liab. Charges                       0             0             0
  Minority Interest                               0             0             0
  Negative Goodwill                               0             0             0

Total Liabilities                            32,037        23,890        12,179

Stockholder Equity:
  Misc. Options, Warrants                         0             0             0
  Redeemable Preferred Stock                      0             0             0
  Preferred Stock                                 0             0             0
  Common Stock                              383,020       329,720       307,766
  Retained Earnings                        -360,877      -343,591      -324,025
  Treasury Stock                                397           190        -3,150
  Capital Surplus                                 0             0             0
  Other Stockhohlder Equity                     397           190             0
  Total Stockholder Equity                   22,540       -13,681       -19,409

Net Tangible Assets                          22,540       -13,681       -22,326


Vericel Corporation (VCEL)                  [Indices near +3.0, near zero,
                                            or < zero bear special attention.]
P/E Ratio Tests:
P/E Ratio < 28?            0.0000          P/E Ratio > 5?             0.0000
P/E Ratio Vs Growth Rate:  0.0000          Forward P/E Ratio < 28?    0.0000
Price/Sales Ratio < 2.3?   0.2573          Inventory/Sales < 5%?      0.8427
Sales < $1 Billion?        3.0000          Operating Margin < 7.5%?   0.7136

Balance Sheet Tests:
Debt/Equity < 0.40?        2.1870          Long-Term Debt Service:    1.3347
LTD Being Reduced?        -3.0000          Short-Term Debt Service:   3.0000
Current Ratio > 2?         1.9292          Working Capital >= 1.5?    0.3939
Leverage Ratio < 20%?      0.5981          Debt/Assets < 1?           3.0000
Quick Ratio > 1?           3.0000          Inventory Turnover > 1?    0.0481
Share Equity Increase:    -0.9427          Market Cap.< 1.5 Billion?  2.0236
                                           Intangibles < 3% Assets?   3.0000
Income Tests:
Profit Margin < 7.5%?     -2.1066          EPS Annual Growth > 10%?   0.1570
Dividend Yield > 2.0%?     0.0000          EPS 3-yr Growth > 15?      0.2002
Enterprise Value/Revenue   3.0000          EPS Growth Consistent?     0.0000
Enterprise Value/EBITDA:  -3.0000          Collection < 45 days?      0.4314
EPS Qrtly Growth > 10%?    0.0000          Gross Pft/Cur. LTD > 1?    3.0000
                                           Borrowing Int. Rate < 6%? -0.9153
Stock Performance Tests:
Volatility > 25%?          3.0000          % Held by Insiders < 5%?   1.3699
Beta > 1.25?               0.0000          % Held by Institut. < 50?  0.6101
50 Da MA > 200 Da MA?      0.5368          % Held by Institut. > 30?  2.7317
52-Wk Change vs. S&P 500: -3.0000          Short Ratio > 5?           0.8220
Price/Book Value < 3?      0.3842          Short % of Float > 20?     0.7570
Return on Assets > 17%?   -0.3888          Average Volume > 100,000?  3.0000

Cash Flow Tests:
Oper. C.F. > Lever'd C.F:  0.7157          Positive Free Cash Flow?  -1.0000
Positive Oper. Cash Flow? -1.0000          Price to C.F.Ratio < 14?:  0.6284
                                           Cash Flow / Assets > 10%?  3.0000

VCEL   Vericel Corporation                 Overall Zenith Index:      0.7004


[Home]
Financial Statements

VERICEL CORP  (VCEL)                        INCOME STATEMENT

Fiscal year ends in December.                        2013-12         2014-12         2015-12         2016-12         2017-12             TTM           

Revenue                                               19,000      28,796,000      51,168,000      54,383,000      63,924,000      82,872,000
Cost of revenue                                        4,000      17,293,000      26,470,000      28,307,000      30,354,000      31,920,000
Gross profit                                          15,000      11,503,000      24,698,000      26,076,000      33,570,000      50,952,000


Operating expenses
Research and development                          15,104,000      21,263,000      18,890,000      15,295,000      12,944,000      14,168,000
Sales, General and administrative                  5,875,000      13,774,000      22,479,000      27,388,000      35,610,000      45,497,000
Total operating expenses                          20,979,000      35,037,000      41,369,000      42,683,000      48,554,000      59,665,000

Operating income                                 -20,964,000     -23,534,000     -16,671,000     -16,607,000     -14,984,000      -8,713,000
Interest Expense                                      11,000           6,000           9,000         314,000       1,107,000       1,569,000
Other income (expense)                             5,353,000       3,620,000         340,000      -2,645,000      -1,195,000      -2,810,000
Income before taxes                              -15,622,000     -19,920,000     -16,340,000     -19,566,000     -17,286,000     -13,092,000
Net income from continuing operations            -15,622,000     -19,920,000     -16,340,000     -19,566,000     -17,286,000     -13,092,000
Net income                                       -15,622,000     -19,920,000     -16,340,000     -19,566,000     -17,286,000     -13,092,000
Preferred dividend                                         0               0               0       7,579,000               0               0
Net income available to common shareholders      -15,622,000     -19,920,000     -16,340,000     -27,145,000     -17,286,000     -13,092,000

Earnings per share
Basic                                                  -6.95           -2.23           -0.97           -1.18           -0.52           -0.32 
Diluted                                                -6.95           -2.23           -0.97           -1.18           -0.52           -0.32 

Weighted average shares outstanding
Basic                                              3,016,000      11,642,000      23,760,000      23,093,000      33,355,000      38,140,000
Diluted                                            3,016,000      11,642,000      23,760,000      23,093,000      33,355,000      38,140,000

____________________________________________________________________________________________________________________________________________


VERICEL CORP  (VCEL)                        BALANCE SHEET

Fiscal year ends in December.                        2013-12         2014-12         2015-12         2016-12         2017-12             

Assets

Current assets

Cash

Total cash                                         8,059,000      30,343,000      14,581,000      22,978,000      26,862,000

Receivables                                                0       8,231,000      10,919,000      17,093,000      18,270,000
Inventories                                                0       1,920,000       1,379,000       3,488,000       3,793,000
Other current assets                                 417,000         996,000         464,000       1,164,000       1,581,000
Total current assets                               8,476,000      41,490,000      27,343,000      44,723,000      50,506,000

Non-current assets

Property, plant and equipment
Gross property, plant and equipment                4,826,000       7,289,000       9,687,000      10,968,000      10,692,000
Accumulated Depreciation                          -4,087,000      -4,397,000      -5,638,000      -7,093,000      -6,621,000
Net property, plant and equipment                    739,000       2,892,000       4,049,000       3,875,000       4,071,000

Intangible assets                                          0       3,197,000       2,917,000               0               0
Total non-current assets                             739,000       6,089,000       6,966,000       3,875,000       4,071,000

Total assets                                       9,215,000      47,579,000      34,309,000      48,598,000      54,577,000 

Liabilities and stockholders' equity

Liabilities

Current liabilities
Short-term debt                                        6,000               0               0         779,000         350,000
Accounts payable                                   2,355,000       5,824,000       7,588,000       6,535,000       5,552,000
Accrued liabilities                                  321,000       4,576,000       2,262,000       2,090,000       2,880,000
Deferred revenues                                          0               0               0               0         420,000
Other current liabilities                          2,639,000       1,429,000       2,258,000       3,449,000       3,888,000
Total current liabilities                          5,321,000      11,829,000      12,108,000      12,853,000      13,090,000

Non-current liabilities
Long-term debt                                             0         109,000          71,000       9,350,000      18,947,000
Deferred revenues                                          0               0               0       1,687,000               0
Total non-current liabilities                              0         109,000          71,000      11,037,000      18,947,000

Total liabilities                                  5,321,000      11,938,000      12,179,000      23,890,000      32,037,000 

Stockholders' equity

Preferred stock                                   38,389,000      38,389,000      41,539,000      38,389,000               0
Additional paid-in capital                       253,270,000     305,008,000     307,766,016     329,720,000     383,020,000
Retained earnings                               -287,764,992    -307,684,992    -324,024,992    -343,591,008    -360,876,992
Treasury stock                                             0               0      -3,150,000               0               0
Accumulated other comprehensive income                     0         -71,000               0         190,000         397,000
Total stockholders' equity                         3,894,000      35,641,000      22,130,000      24,708,000      22,540,000
Total liabilities and stockholders' equity         9,215,000      47,579,000      34,309,000      48,598,000      54,577,000

____________________________________________________________________________________________________________________________________________


VERICEL CORP  (VCEL)                        Statement of CASH FLOW

Fiscal year ends in December. USD.                   2013-12         2014-12         2015-12         2016-12         2017-12             TTM           

Cash Flows From Operating Activities
Net income                                       -15,622,000     -19,920,000     -16,340,000     -19,566,000     -17,286,000     -13,092,000
Depreciation & amortization                          489,000         752,000       1,592,000       1,886,000       1,612,000       1,559,000
Investment/asset impairment charges                        0               0        -268,000       2,638,000               0               0
Stock based compensation                             926,000         839,000       2,747,000       2,499,000       2,680,000       6,366,000
Change in working capital                           -399,000      -2,520,000      -1,412,000      -8,161,000      -1,567,000        -535,000
Accounts receivable                                        0               0      -2,728,000      -6,174,000      -1,177,000         -98,000
Inventory                                                  0         119,000         -86,000      -2,245,000        -657,000         -12,000
Accounts payable                                           0       2,773,000       1,726,000      -1,076,000      -1,361,000      -1,505,000
Accrued liabilities                                  237,000               0               0         920,000               0               0
Other working capital                               -636,000      -5,412,000        -324,000         414,000       1,628,000       1,080,000
Other non-cash items                              -5,337,000      -4,561,000         335,000         812,000       1,378,000       3,513,000
Net cash provided by operating activities        -19,943,000     -25,410,000     -13,346,000     -19,892,000     -13,183,000      -2,189,000

Cash Flows From Investing Activities
Investments in property, plant, and equipmen         -40,000        -829,000      -2,427,000      -1,415,000      -1,510,000      -2,819,000
Acquisitions, net                                          0      -1,450,000               0               0               0               0
Other investing activities                                 0         101,000          35,000               0               0     -44,480,000
Net cash used for investing activities               -40,000      -2,178,000      -2,392,000      -1,415,000      -1,510,000     -47,299,000

Cash Flows From Financing Activities
Debt issued                                                0               0               0      12,900,000      14,793,000               0
Debt repayment                                       -34,000          -8,000         -35,000      -2,438,000      -8,040,000               0
Common stock issued                               14,438,000      49,934,000          11,000      19,455,000       8,220,000      78,248,000
Other financing activities                                 0               0               0        -213,000       3,604,000       9,063,000
Net cash provided by (used for) financing         14,404,000      49,926,000         -24,000      29,704,000      18,577,000      87,311,000

Effect of exchange rate changes                            0         -54,000               0               0               0               0
Net change in cash                                -5,579,000      22,284,000     -15,762,000       8,397,000       3,884,000      37,823,000
Cash at beginning of period                       13,638,000       8,059,000      30,343,000      14,581,000      22,978,000      15,466,000
Cash at end of period                              8,059,000      30,343,000      14,581,000      22,978,000      26,862,000      53,289,000

Free Cash Flow
Operating cash flow                              -19,943,000     -25,410,000     -13,346,000     -19,892,000     -13,183,000      -2,189,000
Capital expenditure                                  -40,000        -829,000      -2,427,000      -1,415,000      -1,510,000      -2,819,000
Free cash flow                                   -19,983,000     -26,239,000     -15,773,000     -21,307,000     -14,693,000      -5,008,000
____________________________________________________________________________________________________________________________________________





[Home]
Average to Current P/E Ratios
              (VCEL)     Vericel Corp.

                               2013    2014    2015    2016    2017

          Annual Earnings:    -6.95   -2.23   -0.97   -1.18   -0.52
Average Price During Year:    12.73    3.47    3.17    2.64    3.36

                P/E Ratio:     1.83    1.55    3.27    2.23    6.46

 Average 5-Year P/E Ratio  =   3.07
             Current Price =  17.04

Previous 5 Quarter Earnings:  -0.16    0.01   -0.21   -0.12   -0.02

          Current Annualized (Last Four Quarters) Earnings =  -0.35
                                                           ________
                                 Average PE / Current PE =    -0.06
                                                           --------

                                      ...a number above 1.00 is good
                                                1.00 or below is bad


[Home]
Financial Ratios

. . . . . . . . . . . . Lowest to Highest, Compared to Industry



[Home]
Intrinsic Value (DCF)

Intrinsic Value by Discounted Cash Flow Method:

Intrinsic Value



[Home]
Fair Value Estimator

Fair Value Estimate:

Fair ValueFair Value



[Home]
Projected Earnings

Earnings Estimates



[Home]
Research Reports

Click Here for Research Reports



[Home]
Analysts' Opinions

Analysts' Opinion 1
Analysts' Opinion 1
Analysts' Opinion 1
Analysts' Opinion 2



[Home]
Insider Activity

Insiders Chart Insider Trades
Executive Compensation Executive Compensation



[Home]
Institutional Activity

Institutional Orders to Buy or Sell:

institutions 1
Ownership:

institutions 2


[Home]
Sentiment

sentiment

Zenith uses the "sentiment" score above or below 50 to award a positive or negative point in the Decision Matrix.

sentiment sentiment sentiment



[Home]
Short Interest Ratio

As the short interest rises as a percentage of average daily share volume (Days to Cover), this is considered a measure of negative sentiment. Similarly, a decrease in that percentage is considered positive sentiment.

short interest short interest


[Home]
Standard & Poor's

S&P Stock Report (Requires Adobe Acrobat Reader)



[Home]
Management's Discussion of Results of Operations Excerpts

Click Here for Management's Discussion Excerpts



[Home]
Channeling Potential

 
The summary below includes a value for `Degree,' which refers on a
scale of 1 to 10 the range of a channel in the period under consi-
deration compared to the total range of price movement. It also looks
for the last closing price to be within the channel, otherwise zeroed.
The `Index' is the `Degree' weighted for volatility.  Generally, the
the higher the index, the more suitable is the stock for trading as
a `rolling stock' between channel high and low points.

Results for VERTICEL CORPORATION:
Symbol? VCEL
Total Months Available:  25
       Months in Cycle?   4

Months Covered by Periods:  12

Period 1           Period 2          Period 3
   H1      L1        H2      L2        H3      L3
  13.20    4.45     14.75    8.95     18.87   10.30

RANGE   =  18.87  TO    4.45            Close =  17.04
CHANNEL =  13.20  TO   10.30           Degree =   2
Volatility =  17.02%                    Index =   3
Channel Chart



[Home]
MACD Histogram Divergence

The theory is that connecting the two most recent peaks or valleys of the MACD histogram will signal the direction of the next major move.



[Home]
Intraday Chart

2 Days:



[Home]
Val Idea

1 out of 8 favorable, (negative opinion.)

Val Idea
Val Idea


[Home]
Stock Consultant

Stock Consultant Stock Consultant


[Home]
Point & Figure Chart

P & F Chart


[Home]
Wall Street Analyzer



[Home]
Marketspace Chart

Marketspace Chart



[Home]
Time Series Forecast

Time Series 1 Time Series 2


[Home]
Neural Network Prediction

"Neurostock" can only track long trades. Therefore its performance, as tracked by itself on stocks which are consistently falling, may not appear as good as it could if each "sell" signal were a "short sale."

Neural Chart
Heading
Neural Trades Neural Prediction



[Home]
Ultimate Trading Systems

2 out of 3 of the ultimate systems favor a downmove.


System Below:
Short term outlook: Positive: Bright Green, Negative: Bright Red
Long term outlook: Postive: Dark Green, Negative: Dark Red.




[Home]
Recommendation

Decision Weighting Factors
FactorsWeighted Points
News - 1
Comparison + 1
Industry - 1
Bond Issue 0
Zenith Index - 1
Non-GAAP vs. GAAP Earnings + 1
Cash Flow + 1
Average to Current P/E - 1
Ratios - 1
Intrinsic Value DCF 0
Fair Value Estimator - 1
Projected Earnings + 1
Research Reports - 1
Analysts + 1
Executive Perquisites - 1
Insider Activity - 1
Institutional Activity + 1
Management Reporting - 1
Short Interest + 1
Sentiment + 1
Standard & Poor's + 1
MACD Histogram Divergence - 1
Val Idea - 1
Stock Consultant + 1
Point & Figure + 1
Wall Street Analyzer - 1
Marketspace Chart + 1
Time Series Chart - 1
Neural Network - 1
Stock Options + 1
Ultimate Trading Systems - 1
Total - 2
Place 1,740 shares of Vericel Corporation (VCEL) on the Active List.